Kenneth C Frazier bought $2.0M of Eikon Therapeutics (EIKN)
Executed Feb 4, disclosed Feb 6, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 6), the stock returned -2.0% (delay-adjusted); from the execution session (Feb 5), -15.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Kenneth C Frazier (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Eikon Therapeutics, Inc. (EIKN). Across 1 priced purchase filing, the average 21-session return was -15.7% from execution and -2.0% from disclosure (delay-adjusted; derived). The largest single filing was $2.0M of EIKN (111,111 sh × $18.00, as filed), executed Feb 4.
Healthcare · Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→